Claudio Lunardi
University of Verona
Genome-wide association studyPathologyAntigenSingle-nucleotide polymorphismAntibodyDermatologyAutoantibodyRheumatologyImmunologyFood allergyArthritisAutoimmune diseaseDiseaseAutoimmunityPathogenesisGeneticsMedicineBiologyImmune systemGastroenterology
235Publications
35H-index
5,115Citations
Publications 240
Newest
#1Alessandra Bettiol (UniFI: University of Florence)H-Index: 12
#2Renato Alberto Sinico (University of Milano-Bicocca)H-Index: 34
Last. Giacomo Emmi (UniFI: University of Florence)H-Index: 27
view all 74 authors...
ABSTRACT Background and objective Systemic small vessel vasculitides carry an increased risk of acute arterial and venous thromboembolic events (AVTE); however, this risk has not been systematically explored in Eosinophilic Granulomatosis with Polyangiitis (EGPA). This study assessed the occurrence and main risk factors of AVTE among EGPA patients as compared to the general community from the population-based Bruneck cohort. Methods We conducted a retrospective multicenter cohort study on 573 EG...
1 CitationsSource
#1Marco Caminati (University of Verona)H-Index: 16
#2Ernesto Crisafulli (University of Verona)H-Index: 22
Last. Gianenrico Senna (University of Verona)H-Index: 37
view all 9 authors...
1 CitationsSource
#1Marco Caminati (University of Verona)H-Index: 16
#2Alessandro Giollo (University of Verona)H-Index: 11
Last. Claudio Lunardi (University of Verona)H-Index: 35
view all 4 authors...
We read with great interest the Brief Report "Use of Biologics to Treat Relapsing and/or Refractory Eosinophilic Granulomatosis with Polyangiitis: data from a European Collaborative Study" by Canzian et al, recently published in Arthritis & Rheumatology (1). It probably provides the largest real-life contribution on EGPA and biologic drugs. Despite the increasing evidence on the topic, including clinical trials and real life studies (2,3), identifying the most appropriate biologic treatment stil...
Source
#1Marco Caminati (University of Verona)H-Index: 16
#2Matteo Maule (University of Verona)H-Index: 1
Last. Claudio Lunardi (University of Verona)H-Index: 35
view all 5 authors...
Source
#1Marco Caminati (University of Verona)H-Index: 16
#2Matteo Maule (University of Verona)H-Index: 1
Last. Claudio Lunardi (University of Verona)H-Index: 35
view all 5 authors...
2 CitationsSource
#1Dilia GiuggioliH-Index: 24
#2Cosimo BruniH-Index: 16
Last. M. Matucci CerinicH-Index: 23
view all 14 authors...
Source
#1Vincenzo BronteH-Index: 70
#2Stefano UgelH-Index: 24
Last. Oliviero OlivieriH-Index: 53
view all 30 authors...
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the ongoing pandemic coronavirus disease 2019 (COVID-19). The majority of patients with COVID-19 have a good prognosis, but variable percentages in different countries develop pneumonia associated with lymphocytopenia and severe inflammatory response due to uncontrolled release of cytokines. These immune mediators are transcriptionally regulated by JAK-STAT molecular pathways, which can be disabled by small mo...
43 CitationsSource
#1Alessandra Bettiol (UniFI: University of Florence)H-Index: 12
#2R Sinico (University of Milano-Bicocca)H-Index: 2
Last. Giacomo Emmi (UniFI: University of Florence)H-Index: 27
view all 74 authors...
Source
#1Vincenzo BronteH-Index: 70
#2Stefano UgelH-Index: 24
Last. Oliviero OlivieriH-Index: 53
view all 30 authors...
Background COVID-19 patients develop pneumonia generally associated to lymphopenia and severe inflammatory response due to uncontrolled cytokine release. These mediators are transcriptionally regulated by the JAK-STAT signaling pathways, which can be disabled by small molecules. Methods A group of subjects (n = 20) was treated with baricitinib according to an off-label use of the drug. The study was designed as an observational longitudinal trial and approved by the local ethical committee. The ...
6 CitationsSource
#1Luca Navarini (Università Campus Bio-Medico)H-Index: 11
#2Francesco CasoH-Index: 30
Last. Antonella Afeltra (Università Campus Bio-Medico)H-Index: 34
view all 22 authors...
The performance of seven cardiovascular (CV) risk algorithms is evaluated in a multicentric cohort of ankylosing spondylitis (AS) patients. Performance and calibration of traditional CV predictors have been compared with the novel paradigm of machine learning (ML). A retrospective analysis of prospectively collected data from an AS cohort has been performed. The primary outcome was the first CV event. The discriminatory ability of the algorithms was evaluated using the area under the receiver op...
Source